Communication, Coordination und Security for People with Multiple Sclerosis - COCOS-MS

niversität zu Köln0 个研究点目标入组 80 人开始时间: 2021年1月11日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Patients with:
•1) Highly active MS with an indication for an escalating immunotherapeutic agent and being treated with such, and at least one of the following: age = 50, expanded disability status scale (EDSS) = 5 (Subgroup 1)
•2a) Primary or secondary chronic progressive MS, age = 18, EDSS 4-7, no immunotherapeutic treatment options (Subgroup 2a)
•2b) Primary or secondary chronic progressive MS, age = 18, EDSS > 7 (Subgroup 2b)
•- residence in the administrative district of Cologne
•AND one of the following criteria applies:
•- full command in understanding, reading, responding of German language skills and ability to give written informed consent
•- if a patient is unable to give consent, a legal representative with a full command of the German language (understanding, reading, responding) and is able to give written informed consent can act on behalf of the patient
•Caregivers:
•- age = 18
•- responsible for caring for the patient
•- full command of the German language (understanding, reading, responding)
•- ability to give written informed consent

•- lack of consent to follow protocol
•- current drug abuse, alcohol abuse or psychiatric illness, which, in the opinion of the trial physician obtaining informed consent, renders the patient or caregiver unfit for participation
•- any kind of dependency on the PCI or sponsor (including being employed there)
•- legal incapacity (caregivers only)

发起方

niversität zu Köln